Bisphosphonate Drugs Fosamax and Boniva Provide No Clinical Benefit for Women in Pre-Menopause

By Rheingold Giuffra Ruffo & Plotkin LLP

By: George Mikhail

According to Consumer Reports Magazine’s team of medical consultants, there is no need for women suffering osteopenia to take drugs such as Fosamax, Boniva or Actonel. Not only do the drugs provide little to no benefit for women in pre-menopause, they have serious side effects. The bisphosphnate drugs are believed to prevent loss of bone mass; however, one of the side effects is the increased risk of fracturing the femur bone. In addition to femur fracture, there are many other painful side effects: ulcers of the stomach and esophagus, inflammation in the eye, muscle and joint pain and fractures of the jawbone.

Bisphosphonate manufacturers knew this information all along, yet continue to heavily market these drugs to women. The FDA has never suggested any of this information, having the public rely on Consumer Reports Magazine. None of this comes as a surprise to our trial attorneys.

Related Posts